FGFR2 and cholangiocarcinoma: Two phase I clinical trials which have been published demonstrated the safety and efficacy of derazantinib in FGFR2 fusion‐positive intrahepatic cholangiocarcinoma and urothelial cancer with FGFR2 and FGF19 amplification.147, 148